HIV is a very dangerous disease that consumes the immune system of the body. It leaves the body vulnerable to any bacteria that enters leading to death as a conclusion. This disease is one of the most dangerous disease on our planet and has no treatment nor any medication to even control it.
A recent study conducted by a team of scientists from the National Institute of Allergy and Infectious Diseases (NIAID), a component of the National Institutes of Health and the United Biopharma, Inc, was able to find an antibody that might suppress HIV. The study was published in The New England Journal Of Medicine. The study focuses on patients who stop their antiretroviral therapy (ART) regimens for a short while; where results show that certain antibodies can suppress HIV for a period of 4 month.
The main antibody that acts upon HIV is UB-421. The study was led by PhD holder Chang Yi Wang, who is the Chief Scientific Officer and Chairperson of United BioPharma, Inc. The study included the use of 29 patients who use oral ART for their HIV infection. Dividing the participants into groups, 14 patients received eight injections of the antibody weekly while the other 15 participants received the injections bi-weekly.
After being done with the course of antibody, the use of ART was restored to all patients. The results showed that all participants had a suppression of HIV during that period, which lasted up to 4 month; during the absence of ART.